accountlast new approach to cancertargeting mutated or overactive genesled to Gleevec, a leukemia drug sold by Novartis, and Pfizer's (PFE) Sutent for kidney cancer. Both topped $1 billion in annual sales within five years of their debuts. Scientists since the...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Big Pharma Bets on a Novel Cancer Cure
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account